Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04563650

COVID-19 Serology and Immunosenescence

This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors.

This study also aims to stratify seroconversion by immunological profiles of the elderly patients residing in the EHPAD. This stratification requires the measurement of immunological marker levels already described in immunosenescence and also involved in the development of certain chronic infectious diseases more common in the elderly population. This analysis will enable the investigators to describe an immunological, clinical and biological profile representing a patient who has developed an immunity against COVID 19. It will also help the investigators to understand the different mechanisms leading to a reduced immune response after a potential administration of a vaccine. Finally, it will help describe the immune profiles of elderly residents who presented with non-severe forms of COVID-19.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Covid19 Blood-Borne Infections COVID-19 Communicable Diseases Coronaviridae Infections Coronavirus Infections Genital Diseases Geriatric Medicine HIV Infections HIV Seropositivity Immune System Diseases Immunologic Deficiency Syndromes Immunosenescence Infections Lentivirus Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Retroviridae Infections Seroconversion Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Amiens

Amiens, 80480, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Residents of the EHPAD/USLD St Victor of the Amiens CHU who took part in the screening campaign (RT-PCR and serology) organized by the Amiens CHU
  • residents who signed a consent form to participate in the study

Exclusion criteria

  • The patient or his legal representative refused to participate in the study
  • Heavily sedated patients

Treatment and study plan

Blood sample

Biological

Sample collection of 4 to 10 tubes of whole blood will be done according to centre Saint-Victor's protocol.

Primary outcomes

  1. titers of COVID-19 neutralising antibodies

    Time frame: day 0

  2. titers of COVID-19 neutralising antibodies

    Time frame: at 3 months

  3. titers of COVID-19 neutralising antibodies

    Time frame: at 6 months

  4. titers of COVID-19 neutralising antibodies

    Time frame: at 9 months

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Official study title

Kinetics of COVID-19-neutralising Antibodies in Patients Residing in EHPAD / USLD: Influence of Immunosenescence

Acronym: SERO-CoV-OLD

Important dates

Study start
2020
Primary completion
2021
Study completion
2026
First posted
Sep 24, 2020
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.